A safe and effective medication designed to prevent mild-to-moderate COVID-19 infections from becoming more dangerous has been available for almost two years. But recent studies have shown many patients eligible for the drug—Paxlovid—haven't been prescribed it. In a clinical trial, the orally...
Putrino believes the failure to study more severe patients stems from a lack of creativity rather than an inability to do so.He points to an ongoing studyhe’s co-authoring with Yale researchers examining the effects of a 15-day Paxlovid course on long COVID symptoms. This study was complet...